SCHEMBL13477351

SCHEMBL13477351

N#Cc1ccc(Sc2ccc(Sc3nnc[nH]3)nc2C(=O)NC2=NCCS2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.48
RAB9A P51151 6/20 0.48
GCK P35557 8/20 0.37
SMN1; SMN2 Q16637 4/20 0.34
TP53 P04637 2/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
NFKB1 P19838 1/20 0.34
HTT P42858 1/20 0.34
GFER P55789 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
HSD17B10 Q99714 1/20 0.34
ALDH1A1 P00352 2/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
KDR P35968 1/20 0.33
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13477350 0.89 GCK (0.47) NPC1RAB9AGCKSMN1; SMN2TP53
SCHEMBL13477353 0.88 GCK (0.40) NPC1RAB9AGCKSMN1; SMN2TP53
SCHEMBL13477355 0.86 KMT2A (0.38) NPC1RAB9AGCKSMN1; SMN2TP53
SCHEMBL13477363 0.85 GCK (0.40) NPC1RAB9AGCKSMN1; SMN2TP53
SCHEMBL13477358 0.84 GCK (0.51) NPC1RAB9AGCKSMN1; SMN2TP53
SCHEMBL13477349 0.83 GCK (0.50) NPC1RAB9AGCKSMN1; SMN2TP53
SCHEMBL13477364 0.82 GCK (0.40) NPC1RAB9AGCKSMN1; SMN2TP53
SCHEMBL13477360 0.81 GCK (0.48) NPC1RAB9AGCKSMN1; SMN2TP53
SCHEMBL13477362 0.81 GCK (0.35) NPC1RAB9AGCKSMN1; SMN2TP53
SCHEMBL13477361 0.81 NPC1 (0.40) NPC1RAB9AGCKSMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8344003-B2 2-pyridinecarboxamide derivatives MSD K. K. (JP) 2013-01-01 US disclosed
US-20100041660-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES MSD K.K. (JP) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041660-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES GCKR, GCK, HK2 NPC1 4261/4885RAB9A 3609/4885GCK 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.